Predictive autoantibodies before the diagnosis of type I diabetes in adults
4 affiliations
- 1Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland, United States of America.
- 2Department of Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland, United States of America.
- 3Department of Medicine, Uniformed Services University, Bethesda, Maryland, United States of America.
- 4Critical Care Medicine Department, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, United States of America.
Abstract
Recent epidemiologic studies indicate that adult-onset type 1 diabetes (AOT1D) is more common than childhood-onset type 1 diabetes, yet it remains clinically underrecognized. Because little is known about the emergence of islet autoantibodies in AOT1D, we conducted a retrospective study using electronic medical records from the United States Military Health System and longitudinal serum samples from 169 individuals with AOT1D and 40 healthy controls obtained from the Department of Defense Serum Repository. Among 643 prediagnostic samples from individuals with AOT1D, IA-2 autoantibodies were the most prevalent (50%), followed by GADA (46%), IA-2β (34%), ZnT8-R (27%), and ZnT8-W (15%). Overall, 85% (144/169) of subjects were seropositive for at least one autoantibody prior to diagnosis. Analysis of the earliest available sample from all of the AOT1D cases, grouped into 5-year intervals preceding diagnosis, demonstrated a progressive increase in seropositivity over time: 38% of subjects were seropositive more than 20 years before diagnosis, increasing to 44% at 20–15 years, 59% at 15–10 years, 73% at 10–5 years, and 91% within 5 years of diagnosis. Among the 144 seropositive individuals, positivity for two or more autoantibodies was the most common pattern, occurring in 50% (72/144) of cases. Isolated GADA positivity (22%) and isolated IA-2/IA-2β positivity (24%) occurred at similar frequencies, whereas isolated ZnT8 positivity was uncommon (4%). Temporal analysis showed that isolated GADA positivity appeared earliest, with a median onset of 7.9 years before diagnosis, whereas multiple-autoantibody positivity, IA-2/IA-2β positivity, and ZnT8 positivity emerged later, with median onsets of 4.6, 4.5, and 1.9 years before diagnosis, respectively. These findings extend observations from pediatric type 1 diabetes to adults and demonstrate that AOT1D-associated autoimmunity often begins decades before clinical diagnosis, highlighting a potentially important window for risk stratification and preventive intervention.
Related
- Quantification of Anti-Ro52, Anti-Ro60 and Anti-La Autoantibodies at High Sample Dilution and Their Predictive Value for Congenital Heart Block.
- International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes: a nominal group technique process
- Serum proteins predict incident inflammatory bowel disease 14 years before diagnosis: a machine-learning and Cox modelling in the UK Biobank
- The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes
- Integrated longitudinal metabolic monitoring before, during and after teplizumab in an adult with stage 2 type 1 diabetes: a case report
BibTeX
@article{burbelo2026predictive,
title = {{Predictive autoantibodies before the diagnosis of type I diabetes in adults}},
author = {Peter D Burbelo and Robert Nee and Julio A Huapaya and Richard Plasse and Myungjin Kim and Sarah Gordon and Giovanni Di Pasquale and John A Chiorini and Stephen Olson},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0352531},
url = {https://doi.org/10.1371/journal.pone.0352531},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Predictive autoantibodies before the diagnosis of type I diabetes in adults
AU - Peter D Burbelo
AU - Robert Nee
AU - Julio A Huapaya
AU - Richard Plasse
AU - Myungjin Kim
AU - Sarah Gordon
AU - Giovanni Di Pasquale
AU - John A Chiorini
AU - Stephen Olson
PY - 2026
DA - 2026/10/15
JO - PLOS One
DO - 10.1371/journal.pone.0352531
UR - https://doi.org/10.1371/journal.pone.0352531
AB - Recent epidemiologic studies indicate that adult-onset type 1 diabetes (AOT1D) is more common than childhood-onset type 1 diabetes, yet it remains clinically underrecognized. Because little is known about the emergence of islet autoantibodies in AOT1D, we conducted a retrospective study using electronic medical records from the United States Military Health System and longitudinal serum samples from 169 individuals with AOT1D and 40 healthy controls obtained from the Department of Defense Serum Repository. Among 643 prediagnostic samples from individuals with AOT1D, IA-2 autoantibodies were the most prevalent (50%), followed by GADA (46%), IA-2β (34%), ZnT8-R (27%), and ZnT8-W (15%). Overall, 85% (144/169) of subjects were seropositive for at least one autoantibody prior to diagnosis. Analysis of the earliest available sample from all of the AOT1D cases, grouped into 5-year intervals preceding diagnosis, demonstrated a progressive increase in seropositivity over time: 38% of subjects were seropositive more than 20 years before diagnosis, increasing to 44% at 20–15 years, 59% at 15–10 years, 73% at 10–5 years, and 91% within 5 years of diagnosis. Among the 144 seropositive individuals, positivity for two or more autoantibodies was the most common pattern, occurring in 50% (72/144) of cases. Isolated GADA positivity (22%) and isolated IA-2/IA-2β positivity (24%) occurred at similar frequencies, whereas isolated ZnT8 positivity was uncommon (4%). Temporal analysis showed that isolated GADA positivity appeared earliest, with a median onset of 7.9 years before diagnosis, whereas multiple-autoantibody positivity, IA-2/IA-2β positivity, and ZnT8 positivity emerged later, with median onsets of 4.6, 4.5, and 1.9 years before diagnosis, respectively. These findings extend observations from pediatric type 1 diabetes to adults and demonstrate that AOT1D-associated autoimmunity often begins decades before clinical diagnosis, highlighting a potentially important window for risk stratification and preventive intervention.
SN - 1932-6203
ER -